Doesn’t kill you: makes you weaker

As things stand a scientific assessment would suggest that Britain is Bangladesh for bees.

Here’s a fun experiment. Give your child – or a neighbour’s child, if you don’t have one of your own – a couple of large glasses of Malbec and then send them off to school. The wine probably won’t kill them, just as the neonicotinoid-based pesticides in routine use on our agricultural land aren’t directly killing bees. The child may well make it across the roads safely and get to school, just as most of the bees are still leaving the hive and finding pollen-bearing flowers. The chances are that the child will perform as badly at school that morning as the pesticideridden bees do at bringing back pollen. But you could still choose to label two glasses of wine a safe dose.

Last month, when the UK government told the EU that neonicotinoids aren’t a proven problem for bees, it brandished scientific evidence. Yet the tests it referred to showed little more than whether the likely doses were lethal. They did not look at whether neonicotinoids hamper a bee’s ability to go about its business effectively – to gather pollen, to navigate between flower sources and hives, or to communicate with other members of the colony.

Better tests show that all these activities are hampered by everyday exposure to neonicotinoids, which may have contributed to the ongoing collapse of bee colonies. For instance, studies carried out by researchers at the University of Stirling found that bumblebees will produce 85 per cent fewer queens. And scientists at Royal Holloway, London, discovered that bumblebees exposed to real-world neonicotinoid levels are 55 per cent more likely to get lost while foraging. That makes sense in the light of studies carried out by researchers at the universities of Newcastle and Dundee, which showed a disruptive effect on the honeybee brain, “observed at concentrations . . . encountered by foraging honeybees and within the hive”.

None of this is surprising. These pesticides are toxins that cause disorder in the brain. Just because they don’t cause immediate observable harm to a single bee when the chemicals are assessed individually doesn’t mean they are not a problem when all the various neurotoxins in the bee’s environment accumulate. As the Dundee and Newcastle researchers reported, “exposure to multiple pesticides . . . will cause enhanced toxicity”. There are probably safe doses of gin, vodka and whisky for a toddler. Give those measures all at once, however, and harm will ensue.

Anyone can avoid accepting inconvenient evidence in science, where findings are rarely black and white. A paper published last autumn in the journal Environmental Health Perspectives, for instance, demonstrates how epidemiologists and toxicologists work out the effects of interacting exposures to chemicals in different ways, which can lead to completely different conclusions about whether there is any effect at all.

But arguing over definitions is no good to bees. The collapse of the jerry-built garment factory in Dhaka, Bangladesh, last month offers a salutary lesson applicable to bee-colony collapse: you can rationalise the greedy pursuit of short-term gain all you like, but if catastrophe strikes, you are still responsible for the loss.

Economists put the annual value of insect pollinators to the UK economy at roughly £440m. Moral considerations aside, ensuring that their working conditions are as safe and sustainable as possible seems to make economic good sense. As things stand, however – and soon they might fall – a scientific assessment would suggest that Britain is Bangladesh for bees.

Bees. Photograph: Getty Images

Michael Brooks holds a PhD in quantum physics. He writes a weekly science column for the New Statesman, and his most recent book is At the Edge of Uncertainty: 11 Discoveries Taking Science by Surprise.

This article first appeared in the 13 May 2013 issue of the New Statesman, Eton Mess

Getty Images/ Staff
Show Hide image

The answer to the antibiotics crisis might be inside your nose

The medical weapons we have equipped ourselves with are losing their power. But scientists scent an answer. 

They say there’s a hero in everyone. It turns out that actually, it resides within only about ten percent of us. Staphylococcus lugdunensis may be the species of bacteria that we arguably don’t deserve, but it is the one that we need.

Recently, experts have cautioned that we may be on the cusp of a post-antibiotic era. In fact, less than a month ago, the US Centres for Disease Control and Prevention released a report on a woman who died from a "pan-resistant" disease – one that survived the use of all available antibiotics. Back in 1945, the discoverer of penicillin, Alexander Fleming, warned during his Nobel Prize acceptance speech against the misuse of antibiotics. More recently, Britain's Chief Medical Officer Professor Dame Sally Davies has referred to anti-microbial resistance as “the greatest future threat to our civilisation”.

However, hope has appeared in the form of "lugdunin", a compound secreted by a species of bacteria found in a rather unlikely location – the human nose.

Governments and health campaigners alike may be assisted by a discovery by researchers at the University of Tubingen in Germany. According to a study published in Nature, the researchers had been studying Staphylococcus aureus. This is the bacteria which is responsible for so-called "superbug": MRSA. A strain of MRSA bacteria is not particularly virulent, but crucially, it is not susceptible to common antibiotics. This means that MRSA spreads quickly from crowded locations where residents have weaker immune systems, such as hospitals, before becoming endemic in the wider local community. In the UK, MRSA is a factor in hundreds of deaths a year. 

The researchers in question were investigating why S. aureus is not present in the noses of some people. They discovered that another bacteria, S. lugdunensis, was especially effective at wiping out its opposition, even MRSA. The researchers named the compound created and released by the S. lugdunensis "lugdunin".

In the animal testing stage, the researchers observed that the presence of lugdunin was successful in radically reducing and sometimes purging the infection. The researchers subsequently collected nasal swabs from 187 hospital patients, and found S. aureus on roughly a third of the swabs, and S. lugdunensis on up to 10 per cent of them. In accordance with previous results, samples that contained both species saw an 80 per cent decrease of the S. aureus population, in comparison to those without lugdunin.

Most notably, the in vitro (laboratory) testing phase provided evidence that the new discovery is also useful in eliminating other kinds of superbugs, none of which seemed to develop resistance to the new compound. The authors of the study hypothesised that lugdunin had evolved  “for the purpose of bacterial elimination in the human organism, implying that it is optimised for efficacy and tolerance at its physiological site of action". How it works, though, is not fully understood. 

The discovery of lugdunin as a potential new treatment is a breakthrough on its own. But that is not the end of the story. It holds implications for “a new concept of finding antibiotics”, according to Andreas Peschel, one of the bacteriologists behind the discovery.

The development of antibiotics has drastically slowed in recent years. In the last 50 years, only two new classes of this category of medication have been released to the market. This is due to the fact almost all antibiotics in use are derived from soil bacteria. By contrast, the new findings record the first occurrence of a strain of bacteria that exists within human bodies. Some researchers now suggest that the more hostile the environment to bacterial growth, the more likely it may be for novel antibiotics to be found. This could open up a new list of potential areas in which antibiotic research may be carried out.

When it comes to beating MRSA, there is hope that lugdunin will be our next great weapon. Peschel and his fellow collaborators are in talks with various companies about developing a medical treatment that uses lugdunin.

Meanwhile, in September 2016, the United Nations committed itself to opposing the spread of antibiotic resistance. Of the many points to which the UN signatories have agreed, possibly the most significant is their commitment to “encourage innovative ways to develop new antibiotics”. 

The initiative has the scope to achieve a lot, or dissolve into box ticking exercise. The discovery of lugdunin may well be the spark that drives it forward. Nothing to sniff about that. 

Anjuli R. K. Shere is a 2016/17 Wellcome Scholar and science intern at the New Statesman